Ataraxis plans to launch its first commercial test for breast cancer to U.S. oncologists and aims to impact at least half of new cancer cases by 2030.
Founders
Jan Witowski, Krzysztof Geras
Company Description
Ataraxis AI is focused on using AI to accurately predict cancer outcomes and personalize treatment, potentially avoiding unnecessary chemotherapy for patients.